AbbVie’s Earnings Beat Wall Street’s Estimates. Investors Are Still Worried

Even if you aren't familiar with the name Abby, you've probably seen some of their commercials. >> There's nothing like clearer skin and better movement. >> This week, the company delivered a solid earnings beat driven by its immunology portfolio of drugs that sent the stock up, recovering from recent losses.Yet, investors, they remain on edge. Aby is the undisputed titan of the hundred billion dollar autoimmune disease market. It treats conditions like psoriasis, arthritis, Crohn's disease.For over two dec ...